Peter C. Enzinger

24.8k total citations · 3 hit papers
147 papers, 8.4k citations indexed

About

Peter C. Enzinger is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Peter C. Enzinger has authored 147 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Pulmonary and Respiratory Medicine, 96 papers in Oncology and 63 papers in Surgery. Recurrent topics in Peter C. Enzinger's work include Gastric Cancer Management and Outcomes (74 papers), Esophageal Cancer Research and Treatment (48 papers) and Colorectal Cancer Treatments and Studies (36 papers). Peter C. Enzinger is often cited by papers focused on Gastric Cancer Management and Outcomes (74 papers), Esophageal Cancer Research and Treatment (48 papers) and Colorectal Cancer Treatments and Studies (36 papers). Peter C. Enzinger collaborates with scholars based in United States, Japan and South Korea. Peter C. Enzinger's co-authors include Robert J. Mayer, Charles S. Fuchs, Jeffrey W. Clark, David P. Ryan, Jeffrey A. Meyerhardt, Matthew H. Kulke, Keith Stuart, Lawrence S. Blaszkowsky, Andrew X. Zhu and Alona Muzikansky and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Peter C. Enzinger

140 papers receiving 8.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Esophageal Cancer

2003 2.1k citations Peter C. Enzinger et al. profile →
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

2018 362 citations Manish A. Shah, Takashi Kojima et al. profile →
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

2023 342 citations Kohei Shitara, Florian Lordick et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter C. Enzinger United States	39	4.2k	3.5k	3.4k	2.0k	1.5k	147	8.4k
Tarek Sahmoud Belgium	41	5.1k 1.2×	4.9k 1.4×	3.1k 0.9×	2.1k 1.1×	1.4k 0.9×	130	11.3k
Maria Di Bartolomeo Italy	41	4.7k 1.1×	2.4k 0.7×	1.4k 0.4×	900 0.5×	1.1k 0.7×	248	6.5k
Rosine Guimbaud France	34	7.7k 1.8×	2.5k 0.7×	2.3k 0.7×	1.5k 0.8×	2.0k 1.3×	178	9.5k
Mark M. Zalupski United States	43	4.9k 1.2×	2.4k 0.7×	1.6k 0.5×	1.4k 0.7×	1.2k 0.8×	197	6.9k
Young Suk Park South Korea	41	4.0k 0.9×	2.3k 0.7×	1.9k 0.6×	1.3k 0.7×	575 0.4×	227	6.3k
Catherine Delbaldo France	20	6.3k 1.5×	2.7k 0.8×	1.6k 0.5×	1.8k 0.9×	1.5k 1.0×	48	8.3k
Jörg T. Hartmann Germany	31	3.4k 0.8×	2.7k 0.8×	2.1k 0.6×	762 0.4×	499 0.3×	69	5.8k
Emmanuel Mitry France	39	5.2k 1.2×	2.9k 0.8×	1.2k 0.4×	772 0.4×	1.5k 1.0×	127	6.8k
Mark S. Talamonti United States	35	3.8k 0.9×	1.6k 0.5×	2.3k 0.7×	784 0.4×	1.7k 1.1×	96	6.0k
Antoine Adenis France	40	10.4k 2.5×	5.4k 1.5×	4.0k 1.2×	2.2k 1.1×	1.7k 1.1×	213	14.2k

Countries citing papers authored by Peter C. Enzinger

Since Specialization

Citations

This map shows the geographic impact of Peter C. Enzinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter C. Enzinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter C. Enzinger more than expected).

Fields of papers citing papers by Peter C. Enzinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter C. Enzinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter C. Enzinger. The network helps show where Peter C. Enzinger may publish in the future.

Co-authorship network of co-authors of Peter C. Enzinger

This figure shows the co-authorship network connecting the top 25 collaborators of Peter C. Enzinger. A scholar is included among the top collaborators of Peter C. Enzinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter C. Enzinger. Peter C. Enzinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perez, Kimberly, Matthew H. Kulke, Hui Zheng, et al.. (2025). A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors. The Oncologist. 30(1).

Klempner, Samuel J., Roberto Pazo-Cid, Sara Lonardi, et al.. (2025). Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study. PubMed. 7. 100131–100131. 4 indexed citations

Janjigian, Yelena Y., Michael Cecchini, Kohei Shitara, et al.. (2025). Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precision Oncology. 9(9). e2400456–e2400456. 1 indexed citations

Kim, S-B., Takashi Ogata, Min Hee Hong, et al.. (2025). LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study. Annals of Oncology. 36. S1621–S1622.

Shitara, Kohei, Manish A. Shah, Florian Lordick, et al.. (2024). Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary. Future Oncology. 20(26). 1861–1877. 1 indexed citations

Sun, Jong‐Mu, Antoine Adenis, Peter C. Enzinger, et al.. (2024). LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future Oncology. 20(35). 2709–2721. 2 indexed citations

Shitara, Kohei, Eric Van Cutsem, Florian Lordick, et al.. (2024). Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4036–4036. 4 indexed citations

Wainberg, Zev A., Yoon‐Koo Kang, Keun‐Wook Lee, et al.. (2024). Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 27(3). 558–570. 30 indexed citations

Lordick, Florian, Manish A. Shah, Kohei Shitara, et al.. (2023). 134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology. 34. S1524–S1524. 2 indexed citations

10.

Shah, Manish A., Jaafar Bennouna, Toshihiko Doi, et al.. (2021). KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma. Future Oncology. 17(10). 1143–1153. 78 indexed citations

11.

Wainberg, Zev A., Peter C. Enzinger, Yoon‐Koo Kang, et al.. (2021). Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).. Journal of Clinical Oncology. 39(3_suppl). 160–160. 63 indexed citations

12.

Metges, Jean‐Philippe, Éric François, Manish A. Shah, et al.. (2019). The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Annals of Oncology. 30. iv130–iv130. 24 indexed citations

13.

Shah, Manish A., Takashi Kojima, Peter C. Enzinger, et al.. (2018). Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.. Journal of Clinical Oncology. 36(15_suppl). 4049–4049. 7 indexed citations

14.

Wolpin, Brian M., Douglas A. Rubinson, Xiaoxu Wang, et al.. (2014). Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. The Oncologist. 19(6). 637–638. 289 indexed citations

15.

Brooks, Gabriel A., Thomas A. Abrams, Jeffrey A. Meyerhardt, et al.. (2014). Identification of Potentially Avoidable Hospitalizations in Patients With GI Cancer. Journal of Clinical Oncology. 32(6). 496–503. 120 indexed citations

16.

Shah, Manish A. & Peter C. Enzinger. (2014). Evidence-Based Management of Advanced Gastric Cancer: Current and Emerging Targeted Therapies. Seminars in Oncology. 41(6). S1–S2.

17.

Wolpin, Brian M., Kimmie Ng, Andrew X. Zhu, et al.. (2013). Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. The Oncologist. 18(4). 377–378. 38 indexed citations

18.

Chan, Jennifer A., Keith Stuart, Craig C. Earle, et al.. (2012). Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors. Journal of Clinical Oncology. 30(24). 2963–2968. 207 indexed citations

19.

Enzinger, Peter C., D. P. Ryan, Eileen Regan, et al.. (2008). Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. Journal of Clinical Oncology. 26(15_suppl). 4552–4552. 36 indexed citations

20.

Kulke, Matthew H., Bingyan Wu, David P. Ryan, et al.. (2006). A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors. Digestive Diseases and Sciences. 51(6). 1033–1038. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact